Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy

Uhrbrand, L.; Faurbye, Arild

doi:10.1007/bf00441188

Cited by 236 publications

(47 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this report we point out prognostic factors for positive outcome. INeuropsychopharmacology 8:233-239, 1993J brand andFaurbye 1960;Paulson 1968;Crane 1973;Hershon et al 1972;Jeste et al 1979;Glazer et al 1984Glazer et al , 1990, whereas more recently and more frequently, new fIndings about remissions of TO symptomatology in pa tients receiving continuous NL treatment have been published (Casey 1985;1991;Casey et al 1986;Casey and Gardos 1990;Gardos et al 1988;Bergen et al 1989;Morgenstern et al 1987;Glazer et al 1991).…”

mentioning

confidence: 99%

Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and Persistence

Cavallaro

Regazzetti

Mundo

et al. 1993

Neuropsychopharmacol

View full text Add to dashboard Cite

Rtl!ersible tardive dyskinesia (TO) outcomes have been rrported in long-term neuroleptic (NL)-treated patients. I" this study the course of TO outcomes was followed-up F 3 years in a population of 125 institutionalized schizophrenic patients (mean age 57.8 years) receiving continuous NL treatment. Tardive dyskinesia occurrence I1Ui severity were assessed by means of the Rockland Simpson Scale (RSS). The prevalence of TO rose from 39.2% at the first examination to 52.8% at last follow-up aamination; however, 28.6% of TO-affected patients rtCOVered and 30% improved. Significant risk factors for a persistent TO outcome result included age over 56 years, duration of illness over 30 years, and a total RSS score over 22. Cumulative NL exposure, over 3550 g of chloropromazine equivalents, was also a significant risk factor for TO. Results from this study confirm that there is the possibility of improvement and remission in an aged, long-term institutionalized population of TO patients. In this report we point out prognostic factors for positive outcome. INeuropsychopharmacology

show abstract

mentioning

confidence: 99%

Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and Persistence

Cavallaro

Regazzetti

Mundo

et al. 1993

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Tremor and choreoathetotic movements induced by neuroleptics were first described by Delay et al' Dyskinesia secondary to long-term neuroleptic treatment was then reported by Sigwald et a12 and was subsequently called tardive dyskinesia. 3 From a pharmacological point of view the mechanisms of these two motor disorders are different. Tremor is caused by blockade of dopaminergic receptors4 whereas the generally accepted explanation for tardive dyskinesia is that of functional overactivity of dopaminergic receptors due to hyper-sensitivity induced by "chemical denervation ".58 As regards tardive dyskinesia several discrepancies exist between the animal model and clinical experience in man.…”

mentioning

confidence: 99%

EMG patterns in abnormal involuntary movements induced by neuroleptics.

Bathien¹,

Koutlidis²,

Rondot³

1984

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

“…Reserpine-induced orofacial movements appear late during the course of administration at low doses and persists for a long time following termination of administration [13]. Although reserpine is not classified as a neuroleptic, it has been used as an antipsychotic agent and has been associated with the development of TD [16]. These reserpine-induced orofacial movements in rats also have other features that are consonant with TD.…”

Section: Introductionmentioning

confidence: 95%

Reversal of Reserpine-Induced Orofacial Dyskinesia and Cognitive Dysfunction by Quercetin

Naidu¹,

Singh²,

Kulkarni³

2004

Pharmacology

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a serious neurological syndrome associated with long-term administration of neuroleptics to humans and experimental animals. The pathophysiology of this disabling and commonly irreversible movement disorder is still obscure. It may be caused by a loss of dopaminergic cells or may be due to free radicals as a product of high synaptic dopamine levels. Quercetin is a bioflavonoid with strong antioxidant properties. Repeated treatment with reserpine (1.0 mg/kg) on each other day for a period of 5 days (days 1, 3 and 5) significantly induced vacuous chewing movements (VCMs) and tongue protrusions (TPs) in rats. Chronic treatment with quercetin for a period of 4 weeks to reserpine-treated animals significantly and dose dependently (50 and 100 mg/kg) reduced the reserpine-induced VCMs and TPs. Reserpine-treated animals also showed poor retention of memory in elevated plus-maze task paradigm. Chronic quercetin administration significantly reversed reserpine-induced retention deficits. Biochemical analysis revealed that chronic reserpine treatment significantly induced lipid peroxidation and decreased the glutathione (GSH) levels in the brains of rats. Chronic reserpine-treated rats showed decreased levels of antioxidant defense enzymes, superoxide dismutase (SOD) and catalase. Chronic administration of quercetin dose dependently (50–100 mg/kg) and significantly reduced the lipid peroxidation and restored the decreased GSH levels by chronic reserpine treatment. It also significantly reversed the reserpine-induced decrease in brain SOD and catalase levels in rats. The results of the present study clearly indicated that quercetin has a protective role against reserpine-induced orofacial dyskinesia and memory impairment. Consequently, the use of quercetin as a therapeutic agent for the treatment of TD should be considered.

show abstract

Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy

Cited by 236 publications

References 3 publications

Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and Persistence

Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and Persistence

EMG patterns in abnormal involuntary movements induced by neuroleptics.

Reversal of Reserpine-Induced Orofacial Dyskinesia and Cognitive Dysfunction by Quercetin

Contact Info

Product

Resources

About